^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PDE10 inhibitor

    Related drugs:
    24d
    Neuroinflammatory and Synaptic Roles of Glial Cells in Autism Spectrum Disorder. (PubMed, CNS Neurol Disord Drug Targets)
    Interventions to correct glial dysfunction-e.g., anti-inflammatory medication (e.g., minocycline, ibudilast), gene therapy, and stem cell therapy-are investigated for their potential to restore glia to normal and diminish ASD symptoms. Understanding glial-neuronal communication mechanisms and their role in neuroinflammation offers a hopeful future for accurate, target-specific treatment. Advances in the elucidation of these processes will foretell an enormous increase in therapeutic efficacy and quality of life for individuals with ASD.
    Journal • IO biomarker
    |
    IL6 (Interleukin 6)
    |
    Eyevinal (ibudilast) • minocycline
    3ms
    MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and are Clinically Relevant Across Central Nervous System Disorders. (PubMed, Cancer Res)
    The brain-penetrant drug ibudilast, which prevents the binding of MIF to CD74, decreased brain metastasis in experimental models in vivo and in patient-derived organotypic cultures ex vivo in a primary tumor-agnostic manner. These findings suggest that MIF/CD74-induced reprogramming of myeloid cells in brain disorders is a vulnerability that could be exploited therapeutically against brain metastases, and possibly other brain disorders.
    Journal
    |
    CD74 (CD74 Molecule) • IFNG (Interferon, gamma)
    |
    Eyevinal (ibudilast)
    3ms
    Allevia2: Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome (clinicaltrials.gov)
    P2, N=164, Active, not recruiting, Noema Pharma AG | Trial primary completion date: Feb 2026 --> Jun 2026
    Trial primary completion date
    3ms
    COMBAT-ALS: Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS (clinicaltrials.gov)
    P2/3, N=234, Active, not recruiting, MediciNova | Trial completion date: Dec 2026 --> Apr 2028 | Trial primary completion date: Dec 2025 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    Eyevinal (ibudilast)
    4ms
    RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine (clinicaltrials.gov)
    P2/3, N=460, Completed, University Health Network, Toronto | Suspended --> Completed
    Trial completion
    |
    Eyevinal (ibudilast)
    5ms
    Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users (clinicaltrials.gov)
    P2, N=176, Completed, VA Office of Research and Development | Recruiting --> Completed | N=120 --> 176 | Trial completion date: Jun 2026 --> Oct 2025
    Trial completion • Enrollment change • Trial completion date
    |
    Eyevinal (ibudilast)
    6ms
    Allevia2: Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome (clinicaltrials.gov)
    P2, N=164, Active, not recruiting, Noema Pharma AG | Recruiting --> Active, not recruiting
    Enrollment closed
    8ms
    Allevia2: Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome (clinicaltrials.gov)
    P2, N=180, Recruiting, Noema Pharma AG | Trial completion date: Dec 2026 --> Apr 2026 | Trial primary completion date: Dec 2026 --> Feb 2026
    Trial completion date • Trial primary completion date
    9ms
    COMBAT-ALS: Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS (clinicaltrials.gov)
    P2/3, N=234, Active, not recruiting, MediciNova | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eyevinal (ibudilast)
    10ms
    RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine (clinicaltrials.gov)
    P2/3, N=460, Suspended, University Health Network, Toronto | Trial completion date: Mar 2025 --> Dec 2025 | Active, not recruiting --> Suspended
    Trial completion date • Trial suspension
    |
    Eyevinal (ibudilast)
    11ms
    Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users (clinicaltrials.gov)
    P2, N=120, Recruiting, VA Office of Research and Development | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Eyevinal (ibudilast)
    1year
    MN-166-GBM-1201: Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma (clinicaltrials.gov)
    P1/2, N=64, Completed, MediciNova | Active, not recruiting --> Completed
    Trial completion
    |
    temozolomide • Eyevinal (ibudilast)